<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818414</url>
  </required_header>
  <id_info>
    <org_study_id>SFPRF-112778</org_study_id>
    <nct_id>NCT01818414</nct_id>
  </id_info>
  <brief_title>Same-day Dilapan-S With Adjunctive Misoprostol</brief_title>
  <acronym>DAM</acronym>
  <official_title>Dilapan-S With Adjunctive Misoprostol for Same-day Second Trimester Dilation and Evacuation: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cervical preparation before second trimester dilation and evacuation (D&amp;E) reduces risks and
      complications. Osmotic cervical dilators as well as prostaglandin analogues have been studied
      for cervical preparation. However, the optimal method for cervical preparation, especially
      for D&amp;E procedures that occur on the same day as cervical preparation, is not known. This
      study will investigate misoprostol versus placebo as an adjunct to Dilapan-S for cervical
      preparation for same-day D&amp;E between 16+0 and 20+6 weeks gestation.

      HYPOTHESIS: Administration of 400 µg buccal misoprostol compared to placebo at least 3 hours
      prior to D&amp;E as an adjunct to cervical preparation with Dilapan-S will decrease operative
      time for same-day D&amp;E performed between 16+0 and 20+6 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dilation and evacuation (D&amp;E) is commonly performed for second trimester abortions and
      management of second trimester intrauterine fetal demise (IUFD). Cervical preparation prior
      to second trimester D&amp;E increases safety.

      Osmotic cervical dilators and prostaglandin analogs are used widely for cervical preparation
      before second trimester D&amp;E. Osmotic dilators are placed into the cervical canal, radially
      expand as they absorb moisture and decrease the risk of cervical injury during D&amp;E. Laminaria
      tents are the most commonly used osmotic dilator for D&amp;E cervical preparation but require N18
      h to reach maximum diameter. Dilapan-S®, a synthetic osmotic cervical dilator, has a
      significant dilation effect 2 h after placement with the majority of expansion occurring in
      4-6 h according to the manufacturer.

      Misoprostol is the most commonly used pharmacologic cervical preparation for D&amp;E with
      duration of action between 2 and 4 h after administration. Multiple studies demonstrate the
      safety of misoprostol before early second trimester abortion. One prospective and four
      retrospective studies suggest that same-day cervical preparation with Dilapan-S and/or
      misoprostol for second trimester D&amp;E through 20 weeks is safe and effective. Misoprostol may
      be less effective when used alone compared to overnight osmotic dilators for cervical
      preparation later in the second trimester but has adjunctive benefit on cervical dilation and
      procedure time when used with overnight osmotic dilators between 16 and 24 weeks. The effect
      appears most pronounced at N19 weeks gestation. No prospective studies have been published
      examining misoprostol as an adjunct to osmotic dilators for cervical preparation for same-day
      D&amp;E.

      Administration of adjunctive misoprostol with Dilapan-S has the potential to effectively
      prepare the cervix and decrease operative time for same-day D&amp;E. We compared cervical
      preparation with Dilapan-S with and without adjunctive buccal misoprostol for same-day D&amp;E
      between 16 0/7 and 20 6/7 weeks gestation.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Concerns for safety
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operative Time</measure>
    <time_frame>Day 1 of the study</time_frame>
    <description>The primary outcome will be operative time. Operative time will be measured from initial passage of an instrument into the uterus to start the D&amp;E. The end of operative time will be measured by the removal of the last instrument from the uterus to complete the D&amp;E.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Pain</measure>
    <time_frame>Day 1</time_frame>
    <description>Change in pain from baseline to immediately preoperatively using a 100-mm Visual Analogue Scale (&quot;100-mm Visual Analogue Scale with 0 indicating &quot;no pain&quot; and 100 indicating &quot;worst pain in my life&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Postoperative Satisfaction</measure>
    <time_frame>Day 1</time_frame>
    <description>Patient postoperative satisfaction with cervical preparation method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Providers With Overall Satisfaction</measure>
    <time_frame>Day 1</time_frame>
    <description>Provider overall satisfaction with cervical preparation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Day 1</time_frame>
    <description>Incidence of surgical complications related to D&amp;E</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Therapeutic Abortion</condition>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Misoprostol 400 mcg buccal 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Folic Acid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Folic acid 4 mg buccally 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>400 mcg of buccal misoprostol, 3 hours prior to planned D&amp;E</description>
    <arm_group_label>Misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>4 mg of buccal folic acid, 3 hours prior to planned D&amp;E</description>
    <arm_group_label>Folic Acid</arm_group_label>
    <other_name>folate, vitamin M, vitamin B9</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years (no upper age limit)

          -  Gestational age between 16+0 and 20+6 weeks gestation on day of D&amp;E with confirmation
             of gestational age by ultrasound

          -  Desires D&amp;E for termination of pregnancy or for fetal demise

          -  Able to provide written informed consent

          -  Able to comply with study procedures

          -  English-speaking

        Exclusion Criteria:

          -  Known allergy or contraindication to misoprostol

          -  Pregnancy with a multiple gestation

          -  Known bleeding disorder or current anticoagulation therapy (within one month of
             procedure)

          -  Active bleeding or hemodynamically unstable at enrollment

          -  Signs of chorioamnionitis or clinical infection at enrollment

          -  Signs of spontaneous labor or cervical insufficiency at enrollment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood of Western Pennsylvania</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univeristy of Pittsburgh, Magee-Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Edelman AB, Buckmaster JG, Goetsch MF, Nichols MD, Jensen JT. Cervical preparation using laminaria with adjunctive buccal misoprostol before second-trimester dilation and evacuation procedures: a randomized clinical trial. Am J Obstet Gynecol. 2006 Feb;194(2):425-30.</citation>
    <PMID>16458640</PMID>
  </reference>
  <reference>
    <citation>Goldberg AB, Drey EA, Whitaker AK, Kang MS, Meckstroth KR, Darney PD. Misoprostol compared with laminaria before early second-trimester surgical abortion: a randomized trial. Obstet Gynecol. 2005 Aug;106(2):234-41.</citation>
    <PMID>16055570</PMID>
  </reference>
  <reference>
    <citation>Newmann SJ, Dalve-Endres A, Diedrich JT, Steinauer JE, Meckstroth K, Drey EA. Cervical preparation for second trimester dilation and evacuation. Cochrane Database Syst Rev. 2010 Aug 4;(8):CD007310. doi: 10.1002/14651858.CD007310.pub2. Review.</citation>
    <PMID>20687085</PMID>
  </reference>
  <reference>
    <citation>Fox MC, Hayes JL; Society of Family Planning. Cervical preparation for second-trimester surgical abortion prior to 20 weeks of gestation. Contraception. 2007 Dec;76(6):486-95. Epub 2007 Nov 9.</citation>
    <PMID>18061709</PMID>
  </reference>
  <reference>
    <citation>Wilson LC, Meyn LA, Creinin MD. Cervical preparation for surgical abortion between 12 and 18 weeks of gestation using vaginal misoprostol and Dilapan-S. Contraception. 2011 Jun;83(6):511-6. doi: 10.1016/j.contraception.2010.10.004. Epub 2010 Dec 3.</citation>
    <PMID>21570547</PMID>
  </reference>
  <reference>
    <citation>Patel A, Talmont E, Morfesis J, Pelta M, Gatter M, Momtaz MR, Piotrowski H, Cullins V; Planned Parenthood Federation of America Buccal Misoprostol Waiver Group. Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy. Contraception. 2006 Apr;73(4):420-30. Epub 2006 Jan 23.</citation>
    <PMID>16531179</PMID>
  </reference>
  <results_reference>
    <citation>Boraas CM, Achilles SL, Cremer ML, Chappell CA, Lim SE, Chen BA. Synthetic osmotic dilators with adjunctive misoprostol for same-day dilation and evacuation: a randomized controlled trial. Contraception. 2016 Nov;94(5):467-472. doi: 10.1016/j.contraception.2016.05.008. Epub 2016 May 27.</citation>
    <PMID>27241895</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <results_first_submitted>February 22, 2016</results_first_submitted>
  <results_first_submitted_qc>November 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2017</results_first_posted>
  <last_update_submitted>January 16, 2017</last_update_submitted>
  <last_update_submitted_qc>January 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Christy Boraas</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Misoprostol administration &amp; dosage</keyword>
  <keyword>Abortion techniques</keyword>
  <keyword>Abortion Induced methods</keyword>
  <keyword>Dilatation and Curettage</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Misoprostol</title>
          <description>Misoprostol 400 mcg buccal 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S.
Misoprostol</description>
        </group>
        <group group_id="P2">
          <title>Folic Acid</title>
          <description>Folic acid 4 mg buccally 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S
Folic Acid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Misoprostol</title>
          <description>Misoprostol 400 mcg buccal 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S.
Misoprostol</description>
        </group>
        <group group_id="B2">
          <title>Folic Acid</title>
          <description>Folic acid 4 mg buccally 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S
Folic Acid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Operative Time</title>
        <description>The primary outcome will be operative time. Operative time will be measured from initial passage of an instrument into the uterus to start the D&amp;E. The end of operative time will be measured by the removal of the last instrument from the uterus to complete the D&amp;E.</description>
        <time_frame>Day 1 of the study</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>Misoprostol 400 mcg buccal 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S.
Misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Folic Acid</title>
            <description>Folic acid 4 mg buccally 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S
Folic Acid</description>
          </group>
        </group_list>
        <measure>
          <title>Operative Time</title>
          <description>The primary outcome will be operative time. Operative time will be measured from initial passage of an instrument into the uterus to start the D&amp;E. The end of operative time will be measured by the removal of the last instrument from the uterus to complete the D&amp;E.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" spread="5.4"/>
                    <measurement group_id="O2" value="13.5" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Pain</title>
        <description>Change in pain from baseline to immediately preoperatively using a 100-mm Visual Analogue Scale (&quot;100-mm Visual Analogue Scale with 0 indicating &quot;no pain&quot; and 100 indicating &quot;worst pain in my life&quot;)</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>Misoprostol 400 mcg buccal 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S.</description>
          </group>
          <group group_id="O2">
            <title>Folic Acid</title>
            <description>Folic acid 4 mg buccally 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Pain</title>
          <description>Change in pain from baseline to immediately preoperatively using a 100-mm Visual Analogue Scale (&quot;100-mm Visual Analogue Scale with 0 indicating &quot;no pain&quot; and 100 indicating &quot;worst pain in my life&quot;)</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" spread="25.4"/>
                    <measurement group_id="O2" value="24.3" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Postoperative Satisfaction</title>
        <description>Patient postoperative satisfaction with cervical preparation method</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>Misoprostol 400 mcg buccal 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S.
Misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Folic Acid</title>
            <description>Folic acid 4 mg buccally 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S
Folic Acid</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postoperative Satisfaction</title>
          <description>Patient postoperative satisfaction with cervical preparation method</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Providers With Overall Satisfaction</title>
        <description>Provider overall satisfaction with cervical preparation</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>Misoprostol 400 mcg buccal 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S.</description>
          </group>
          <group group_id="O2">
            <title>Folic Acid</title>
            <description>Folic acid 4 mg buccally 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Providers With Overall Satisfaction</title>
          <description>Provider overall satisfaction with cervical preparation</description>
          <units>providers</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications</title>
        <description>Incidence of surgical complications related to D&amp;E</description>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol</title>
            <description>Misoprostol 400 mcg buccal 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S.
Misoprostol</description>
          </group>
          <group group_id="O2">
            <title>Folic Acid</title>
            <description>Folic acid 4 mg buccally 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S
Folic Acid</description>
          </group>
        </group_list>
        <measure>
          <title>Complications</title>
          <description>Incidence of surgical complications related to D&amp;E</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Misoprostol</title>
          <description>Misoprostol 400 mcg buccal 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S</description>
        </group>
        <group group_id="E2">
          <title>Placebo Comparator: Folic Acid</title>
          <description>Folic acid 4 mg buccally 3 hours prior to D&amp;E as an adjunct to same-day Dilapan-S</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <description>Cervical laceration during dilation and evacuation procedure resulting in hemorrhage treated with uterine artery embolization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <description>Cervical laceration during dilation and evacuation procedure resulting in hemorrhage treated with hysterectomy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christy Boraas, MD, MPH</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-273-7111</phone>
      <email>bora0021@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

